Table 1.
Formulation of 3 Lots of Candidate MMR-RIT (Measles, Mumps, Rubella) Vaccine and Commercially Available Comparator Vaccine (MMRII, Merck & Co., Inc.)
| Vaccine | Lot Number(s) | Log10 CCID50 |
||
|---|---|---|---|---|
| Measlesa | Mumpsb | Rubellac | ||
| MMRII | 1291X | 4.0 | 4.8 | 4.2 |
| 1255X | 3.9 | 4.8 | 4.0 | |
| 1362X | 3.8 | 4.8 | 4.1 | |
| MMR-RIT-1 | AMJRB721A | 3.8 | 4.8 (high) | 3.9 |
| MMR-RIT-2 | DMJRA002A | 4.1 | 4.1 (medium) | 3.9 |
| MMR-RIT-3 | DMJRA003A | 4.0 | 3.7 (low) | 4.1 |
Abbreviation: CCID50, Median cell culture infective dose.
Note: All CCID50 values for vaccine components of MMRII and MMR-RIT were determined by GlaxoSmithKline.
aMeasles was Schwarz strain for GlaxoSmithKline vaccines and Moraten Edmonston-Enders strain for MMRII.
bMumps was RIT 4385 strain for GlaxoSmithKline vaccines and Jeryl Lynn for MMRII.
cRubella strain was the same for MMRII and each MMR-RIT (ie, Wistar RA 27/3).